Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
CG Oncology, Inc. Common stock(CGON)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CGON
09/25/2026: CGON (2-star) is a SELL. SELL for 1 day. Simulated Profits (-8.92%). Updated daily EoD!
CG Oncology is a clinical-stage biotechnology company focused on developing oncolytic immunotherapy to treat bladder cancer. Its primary value proposition centers on the potential of its lead candidate, cretostimogene, to offer a bladder-sparing alternative for patients. While the company has shown positive clinical progress, it currently lacks commercial revenue, making it a high-risk play dependent on binary clinical outcomes. Investors must carefully monitor regulatory developments and clinical trial data readouts. This stock is best suited for growth-oriented investors who can tolerate high volatility and understand the significant risks inherent in early-stage biotechnology research.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth opportunity dependent on binary clinical outcomes. |
| Momentum investor | Mixed fit | Momentum may track clinical news cycles; investors should look for positive signals. |
| Value investor | Weak fit | The company has no earnings or revenue to justify a traditional value-based valuation. |
| Dividend investor | Weak fit | The company is in an early-stage growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | Biotechnology development carries significant volatility and binary risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are highly sensitive to trial results. |
| Valuation risk | High | Valuations are driven by speculative future success rather than cash flows. |
| Competition risk (Oncology immunotherapies) | High | Established players have massive R&D budgets. |
| Business quality | Medium | Quality is tied to clinical execution rather than established market franchises. |
| Dividend income | Low / none | Income generation is not part of the current business model. |
| Execution risk | High | Failure to achieve regulatory approval would severely impact the business. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -53.1% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.09B USD | Price to earnings Ratio - | 1Y Target Price 91.08 |
Price to earnings Ratio - | 1Y Target Price 91.08 | ||
Volume (30-day avg) 816.6K shares | Beta 0.24 | 52 Weeks Range 35.80 - 80.97 | Updated Date 09/25/2026 |
52 Weeks Range 35.80 - 80.97 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.52 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Therapeutics Development | Cretostimogene grenadenorepvec (investigational). | The company is currently spending money to develop a drug and earns no revenue yet. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5.49B | Price to Sales(TTM) 978.63 |
Enterprise Value 5.49B | Price to Sales(TTM) 978.63 | ||
Enterprise Value to Revenue 881.12 | Enterprise Value to EBITDA - | Shares Outstanding 88.64M | Shares Floating 68.28M |
Shares Outstanding 88.64M | Shares Floating 68.28M | ||
Percent Insiders 0.23 | Percent Institutions 113.67 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About CG Oncology, Inc. Common stock
Exchange NASDAQ | Headquarters Dallas, TX, United States | ||
IPO Launch date 2024-01-25 | President, Chairman & CEO Mr. Arthur Kuan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 142 | Website https://cgoncology.com |
Full time employees 142 | Website https://cgoncology.com | ||
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.